USFDA concludes inspection at Lupin’s Pithampur Unit-2 manufacturing facility

18 Jul 2025 Evaluate

United States Food and Drug Administration (USFDA) has concluded inspection at Lupin’s Pithampur Unit-2 manufacturing facility. The inspection closed with the issuance of a Form-483 with four observations. The said inspection was conducted from July 08, 2025 to July 17, 2025. 

The company is addressing these observations comprehensively and will respond to the USFDA within the stipulated timeframe. It upholds quality and compliance with utmost importance and is committed to be compliant with CGMP quality standards across all its facilities. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2120.70 7.55 (0.36%)
18-Dec-2025 12:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1744.20
Dr. Reddys Lab 1278.20
Cipla 1504.15
Zydus Lifesciences 915.50
Lupin 2120.70
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×